Flavia Bonini

Flavia Bonini

Auto-generated profile, based on publicly available information

Flavia Bonini

The University of Texas MD Anderson Cancer Center 1 Department of Thoracic/Head and Neck Medical Oncology Houston, Texas

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2025 in Cancer Medicine
Verified
Journal Article
Open access
CHCamilla O. Hoff
Camilla O. Hoff
LSLuana G. de Sousa
Luana G. de Sousa
FBFlavia Bonini
Flavia Bonini
ELEduardo Dal Lago
Eduardo Dal Lago
KWKaiwen Wang
Kaiwen Wang
RFRenata Ferrarotto
Renata Ferrarotto
Background: Adenoid cystic carcinoma (ACC) with NOTCH‐activating mutations presents a clinical challenge due to its poor prognosis. NOTCH inhibitors have emerged as a potential therapy for ACC patients with NOTCH activation. This study aimed to evaluate the efficacy of NOTCH inhibitors in this patient population.Methods: A retrospective analysis was conducted on patients with metastatic ACC harboring NOTCH pathway activation, who received NOTCH inhibitors at MD Anderson Cancer Center. NOTCH inhibitors included AL101, a gamma‐secretase inhibitor, and brontictuzumab, an antibody targeting NOTCH1. NOTCH pathway activation was assessed through genomic analysis for NOTCH‐activating mutations or immunohistochemistry for NOTCH1 intracellular domain (NICD1). Efficacy endpoints included best overall response (BOR) and progression‐free survival (PFS) per RECIST or MD Anderson bone response criteria.Results: Twenty‐nine patients were included, with a predominance of solid histology (86%). NOTCH‐activating mutations were identified in 82% of patients, and 95% showed positive NICD1 staining. BOR revealed partial response in 17% of patients, stable disease in 55%, and progressive disease in 28%. Median response duration was longer for AL101 compared to brontictuzumab (9.9 vs. 1.7 months, p = 0.04). Median PFS with NOTCH inhibitor was 4.2 months (95% CI 2.7–8.6 months). Progression of nontarget lesions occurred in 34% of patients. Comparison with prior therapy showed longer PFS with NOTCH inhibitors (HR 0.38, 95% CI 0.19–0.78, p = 0.0065).Conclusion: NOTCH inhibitors demonstrate activity in NOTCH‐activated ACC, surpassing the efficacy of observation or prior systemic therapies. However, limited PFS and progression of nontarget lesions suggest the potential need for combination therapy to address ACC heterogeneity.

15 May 2025 in Cancer
Verified
Journal Article
Open access
CHCamilla Oliveira Hoff
Camilla Oliveira Hoff
LFLei Feng
Lei Feng
FBFlavia Bonini
Flavia Bonini
LSLuana G. Sousa
Luana G. Sousa
KWKaiwen Wang
Kaiwen Wang
RFRenata Ferrarotto
Renata Ferrarotto
Background: Adenoid cystic carcinoma (ACC) frequently has pulmonary metastasis (PM). Given limited systemic therapy options, these metastases are often treated with pulmonary metastasis–directed local therapy (PM‐LT), although with unknown impact on overall survival (OS). This single institution, retrospective cohort study investigated the survival outcomes of PM‐LT versus no PM‐LT in ACC.Methods: ACC patients with at least one PM (≥5 mm) were included. PM‐LT was metastasectomy or radiotherapy. Clinicopathologic characteristics were compared between patients with and without PM‐LT. Primary end point was OS from PM diagnosis, with landmark analysis at 6 months, 1 year, 2 years, and 3 years after metastasis diagnosis, with Cox proportional hazards model multivariate analysis and propensity score matching analysis. Subgroup analysis by ACC histology (solid/nonsolid) was performed.Results: Of 219 included ACC, 119 (54%) had no PM‐LT and 100 (46%) did. PM‐LT patients had more nonsolid histology (p = .0008), oligometastases (p < .0001), exclusively PM (p = .02), and longer time to metastasis from diagnosis (p < .0001). On univariate analysis, PM‐LT by 6 months, 1 year, and 2 years, but not by 3 years, increased OS. On multivariate analysis, PM‐LT by 6 months (p = .12), 1 year (p = .08), or 3 years (p = .08) did not significantly increase OS, but PM‐LT by 2‐years had a borderline statistically significant association (p = .045). Of the 104 nonsolid ACC, 50 underwent PM‐LT and 54 did not. On univariate and multivariate analysis, PM‐LT did not increase OS at any time point for nonsolid ACC.Conclusion: This is the largest study of survival outcomes of PM‐LT in metastatic ACC. Findings suggest PM‐LT does not increase OS in unselected ACC.

8 May 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
CHCamilla Oliveira Hoff
Camilla Oliveira Hoff
SHSimon Heeke
Simon Heeke
YMYoshitsugu Mitani
Yoshitsugu Mitani
LSLuana G. de Sousa
Luana G. de Sousa
JSJuliana M. Siqueira
Juliana M. Siqueira
RFRenata Ferrarotto
Renata Ferrarotto
Purpose: The phase II axitinib plus avelumab trial in recurrent/metastatic adenoid cystic carcinoma (ACC) demonstrated favorable response rates and progression-free survival (PFS), leading to its inclusion in National Comprehensive Cancer Network guidelines as the first immunotherapy-based option for ACC. We sought to identify biomarkers predictive of clinical benefit from axitinib plus avelumab. Patients and Methods: Twenty-eight patients with ACC enrolled in the study. Pretreatment tumors underwent whole-exome sequencing, transcriptomic profiling, imaging mass cytometry, and tumor, oral rinse, and stool microbiome characterization using 16S rRNA gene sequencing. Associations with PFS were assessed using the Cox proportional hazards model, incorporating ACC subtype (ACC-I vs. ACC-II) as a covariate. Results: ACC comprises 2 proteogenomically distinct subtypes: aggressive, NOTCH1-activated ACC-I and more indolent ACC-II. Here, the median PFS was 1.8 months for ACC-I versus 11.4 months for ACC-II [hazard ratio (HR), 0.14; P < 0.0001)], representing the first demonstration of subtype-specific clinical trial outcomes in ACC. Clinical benefit was not associated with PD-L1 expression, tumor mutational burden, or recurrent genomic mutations. Instead, improved PFS correlated with the presence of intratumoral Escherichia and gut Bifidobacterium and Akkermansia. Transcriptomic profiling identified a 167-gene immune-enriched signature predictive of PFS benefit with axitinib plus avelumab. This signature also predicted benefit from ipilimumab plus nivolumab but not from regorafenib monotherapy, suggesting its specificity for immunotherapy-based combinations. Conclusions: Clinical trial outcomes with axitinib plus avelumab differ significantly by ACC subtype. Furthermore, the identified 167-gene immune-related signature predicts clinical benefit to immunotherapy-based combinations in ACC. These findings provide a framework for future biomarker-driven trial design and patient stratification strategies for this rare malignancy.

26 August 2025 in Oral Oncology
Verified
Journal Article
Closed access
JSJuliana Mota Siqueira
Juliana Mota Siqueira
DHDaniele Heguedusch
Daniele Heguedusch
MCMateus Trinconi Cunha
Mateus Trinconi Cunha
LSLuana Guimaraes de Sousa
Luana Guimaraes de Sousa
MMMario L. Marques-Piubelli
Mario L. Marques-Piubelli
RFRenata Ferrarotto
Renata Ferrarotto